Moreover, considering that ADAM17 is a major modifier of EGFR signaling, the inhibitors of ADAM17 are hoped to be specifically useful in cancers that are associated with EGFR/HER2/neu pathway and in tumors showing resistance to tyrosine kinases or trastuzumab due to excessive formation of ligands, including TGF-α. Here, EGFR is linked to cancer.